Data di Pubblicazione:
2007
Citazione:
Severe psoriasis treated with a new macrolide : Everolimus / E. Frigerio, M.D. Colombo, C. Franchi, A. Altomare, C. Garutti, G.F. Altomare. - In: BRITISH JOURNAL OF DERMATOLOGY. - ISSN 0007-0963. - 156:2(2007), pp. 372-374. [10.1111/j.1365-2133.2006.07602.x]
Abstract:
Psoriasis is an immune-mediated disease with a chronic relapsing course, and the particularly severe forms that are refractory to traditional therapies are often difficult to manage. Everolimus (Certican®; Novartis, Basel, Switzerland) is a new rapamycin-derived macrolide that is used in the prophylaxis of rejection in heart and kidney transplant patients. The mechanism underlying its immunosuppressant and antiproliferative activity is different from, but complementary to, that of calcineurin inhibitors such as ciclosporin. We describe a woman with severe psoriasis treated with everolimus combined with subtherapeutic doses of ciclosporin.
Tipologia IRIS:
01 - Articolo su periodico
Keywords:
Ciclosporin; Everolimus; Psoriasis
Elenco autori:
E. Frigerio, M.D. Colombo, C. Franchi, A. Altomare, C. Garutti, G.F. Altomare
Link alla scheda completa: